Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04358991 · ClinicalTrials.gov registry record
Pharmacokinetics of Ceftazidime-avibactam Among Critically-ill Patients Receiving CVVHDF
A clinical trial, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 20
- Enrollment target
NCT04358991: Completed study, sponsored by University of Pittsburgh.
NCT04358991 is a clinical trial that has completed, run by University of Pittsburgh. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04358991 has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
Ceftazidime-avibactam is used for treatment of invasive Gram-negative bacterial infections among critically ill patients, including those on continuous venovenous hemodiafiltration . However, dosing of ceftazidime-avibactam for these patients remains undefined. The purpose of this study was to evaluate the pharmacokinetics of ceftazidime and avibactam among critically-ill patients, including those receiving CVVHD. This is a registration of Dr. Shields' exempt project under IRB approved research study STUDY19040363
Primary Outcome
PK samples obtained around standard of care dosing regimens immediately before and at 1, 2, 4, 6, and 8 hours after administration
Interventions
- DRUG Ceftazidime-avibactam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-01-01 |
| Est. Completion | 2019-12-31 |
What the finished NCT04358991 record still lists
NCT04358991 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Ceftazidime-avibactam is the first listed.
NCT04358991 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04358991 about?
NCT04358991 is a clinical study titled "Pharmacokinetics of Ceftazidime-avibactam Among Critically-ill Patients Receiving CVVHDF". Ceftazidime-avibactam is used for treatment of invasive Gram-negative bacterial infections among critically ill patients, including those on continuous venovenous hemodiafiltration . However, dosing of ceftazidime-avibactam for these patients remains undefined. The purpose of this study was to evalu...
What is the current status of trial NCT04358991?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2017-01-01. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT04358991?
The interventions under investigation include: Ceftazidime-avibactam (DRUG).
Who is sponsoring clinical trial NCT04358991?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI